ArticleBlood cancer journal2025

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study.

Jules Higué et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.